Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $44,359.30 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 7,030 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $6.31, for a total transaction of $44,359.30. Following the completion of the transaction, the insider directly owned 401,850 shares of the company’s stock, valued at $2,535,673.50. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The shares were sold at an average price of $7.86, for a total value of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total value of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total value of $19,063.24.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total value of $68,664.20.
• On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The shares were sold at an average price of $6.79, for a total value of $51,624.37.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The shares were sold at an average price of $6.81, for a total value of $74,276.67.
• On Wednesday, December 10th, Chidozie Ugwumba sold 9,921 shares of Clene stock. The stock was sold at an average price of $6.42, for a total value of $63,692.82.
• On Tuesday, December 9th, Chidozie Ugwumba sold 15,031 shares of Clene stock. The shares were sold at an average price of $5.95, for a total value of $89,434.45.
• On Monday, December 8th, Chidozie Ugwumba sold 21,463 shares of Clene stock. The shares were sold at an average price of $5.70, for a total transaction of $122,339.10.
• On Friday, December 5th, Chidozie Ugwumba sold 37,235 shares of Clene stock. The stock was sold at an average price of $5.94, for a total transaction of $221,175.90.

Clene Stock Up 10.6%

Shares of Clene stock opened at $6.68 on Friday. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50. The stock has a market capitalization of $69.00 million, a P/E ratio of -1.97 and a beta of 0.79. The company has a 50-day simple moving average of $8.51 and a 200 day simple moving average of $6.23.

Clene (NASDAQ:CLNN) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. On average, equities analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current year.

Key Stores Impacting Clene

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Sell‑side support remains — several research firms (Benchmark, UBS, D. Boral Capital) continue to carry Buy ratings and elevated targets, which can limit downside and support rebounds. MarketBeat CLNN
• Neutral Sentiment: Institutional activity mixed — some hedge funds increased or initiated positions (e.g., Scoggin Management added shares), meaning a portion of supply is being absorbed by institutions rather than retail. MarketBeat Holdings
• Negative Sentiment: Material insider selling by a major shareholder — Ugwumba disclosed many transactions from Dec. 3–17 totaling roughly ~258k shares sold across multiple days (including a 72,748 share sale on Dec. 4 that was reported as a 12.24% position reduction). Heavy, concentrated selling from a >10% holder puts clear downward pressure and likely explains the intraday weakness. InsiderTrades Article
• Negative Sentiment: Weak recent operating results — the company missed Q3 revenue and EPS expectations (reported -$0.85 vs. consensus -$0.60; revenue essentially immaterial), keeping the story speculative and increasing sensitivity to insider flows. SEC Filing

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on CLNN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. D. Boral Capital restated a “buy” rating and set a $23.00 target price on shares of Clene in a report on Wednesday, December 10th. Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Finally, UBS Group reaffirmed a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.60.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Lunt Capital Management Inc. boosted its position in Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after buying an additional 1,250 shares during the last quarter. Jones Financial Companies Lllp bought a new stake in shares of Clene during the third quarter worth $29,000. Jane Street Group LLC acquired a new position in shares of Clene during the second quarter valued at $47,000. Finally, Scoggin Management LP boosted its holdings in Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after acquiring an additional 42,750 shares during the last quarter. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).